After more than two years of questions raised by clinical data concerning the safety and efficacy of drug-eluting stents (DES), declines in the sales of DES devices because of these questions, and DES developers looking for R&D and regulatory guidance, FDA last month issued a new set of guidelines, in draft form, concerning the development, testing and manufacture of DES devices.